Home Tags SCLC

Tag: SCLC

Independent Data Monitoring Committee Recommends Enrollment to be Stopped for Study...

An Independent Data Monitoring Committee (IDMC) responsible for ongoing review of study data of the TAHOE study, a Phase III study evaluating Rovalpituzumab Tesirine...

Phase II Study Evaluating Rovalpituzumab Tesirine Announced – AbbVie will Not...

After consulting with the U.S. Food and Drug Administration (FDA), AbbVie, a global research and development-based biopharmaceutical company, announced that the company will not...

Researchers Find SCLC-biopsy Specimen Reliable for Evaluating DLL3 Expression

High levels of delta-like protein 3 or DLL3 in small-cell lung cancer or SCLC are correlated with poor survival trends.  Li-Xu Yan, MD, a...

Sacituzumab govitecan (IMMU-132) Demonstrates Therapeutic Potential in the Treatment of Metastatic...

Two prominent cancer journals have published phase II clinical trial results with sacituzumab govitecan (IMMU-132; Immunomedics) in a total of 104 patients with lung...

Collaboration to Explore the Safety and Efficacy of Combining Rova-T +...

A new Phase I/II clinical program in which Bristol-Myers Squibb collaborates with AbbVie will evaluate the safety, tolerability and efficacy of the investigational biomarker-specific...

Rovalpituzumab Tesirine Shows Early Promise in Small Cell Lung Cancer

Rovalpituzumab tesirine (Rova-T or SC16LD6.5; AbbVie), a novel biomarker-specific 'smart-bomb' antibody-drug conjugate or ADC targeting the delta-like protein 3 or DLL3 protein, expressed in more...

Sacituzumab govitecan (IMMU-132) Shows Positive Interim Phase II Results

Sacituzumab govitecan also known as IMMU-132, an antibody-drug conjugate being developed by Immunomedics, a clinical-stage biopharmaceutical company, continues to produce durable responses in patients with...

Novel Targeted Lung Cancer Therapies are Expected to Replace Current Conventional...

Lung cancer, which is mostly a disease of the elderly*, is defined as the uncontrolled growth of abnormal cells in one or both lungs.  Approximately 60%...

ImmunoGen Discontinues IMGN901 Study in Small-Cell Lung Cancer (SCLC)

ImmunoGen has stopped the IMGN901 Phase II SCLC study. The decision is based on the recommendation of the trial's independent Data Monitoring Committee (DMC)....